51B Stock Overview
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Bioventix PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£46.40 |
| 52 Week High | UK£59.00 |
| 52 Week Low | UK£37.80 |
| Beta | 0.39 |
| 11 Month Change | 6.91% |
| 3 Month Change | -9.02% |
| 1 Year Change | 10.48% |
| 33 Year Change | 11.00% |
| 5 Year Change | 31.44% |
| Change since IPO | 47.13% |
Recent News & Updates
Recent updates
Shareholder Returns
| 51B | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 5.9% | -1.9% | -0.6% |
| 1Y | 10.5% | -18.1% | 9.6% |
Return vs Industry: 51B exceeded the German Biotechs industry which returned -18.1% over the past year.
Return vs Market: 51B matched the German Market which returned 9.6% over the past year.
Price Volatility
| 51B volatility | |
|---|---|
| 51B Average Weekly Movement | 6.7% |
| Biotechs Industry Average Movement | 6.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 51B has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 51B's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 12 | Peter Harrison | www.bioventix.com |
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; and Pyrene (HOP-G) ELISA kit to monitor human exposure to industrial pollutants. It also provides contract SMAs and recombinant services.
Bioventix PLC Fundamentals Summary
| 51B fundamental statistics | |
|---|---|
| Market cap | €246.36m |
| Earnings (TTM) | €9.74m |
| Revenue (TTM) | €16.36m |
25.3x
P/E Ratio15.1x
P/S RatioIs 51B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 51B income statement (TTM) | |
|---|---|
| Revenue | UK£13.61m |
| Cost of Revenue | UK£925.53k |
| Gross Profit | UK£12.68m |
| Other Expenses | UK£4.58m |
| Earnings | UK£8.10m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.55 |
| Gross Margin | 93.20% |
| Net Profit Margin | 59.51% |
| Debt/Equity Ratio | 0% |
How did 51B perform over the long term?
See historical performance and comparisonDividends
3.9%
Current Dividend Yield100%
Payout RatioDoes 51B pay a reliable dividends?
See 51B dividend history and benchmarks| Bioventix dividend dates | |
|---|---|
| Ex Dividend Date | Nov 07 2024 |
| Dividend Pay Date | Nov 21 2024 |
| Days until Ex dividend | 8 days |
| Days until Dividend pay date | 6 days |
Does 51B pay a reliable dividends?
See 51B dividend history and benchmarks